LYN - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
CSK	C-terminal Src kinase	GAB1 signalosome Phosphorylation of CD3 and TCR zeta chains Integrin signaling PD-1 signaling MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Negative regulation of FLT3	Dasatinib Staurosporine TG-100801 Fostamatinib
CSNK2B	casein kinase 2 beta	Synthesis of PC WNT mediated activation of DVL Condensation of Prometaphase Chromosomes Signal transduction by L1 Neutrophil degranulation Regulation of TP53 Activity through Phosphorylation Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding Receptor Mediated Mitophagy RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known Regulation of PTEN stability and activity	ATP Quercetin
CTLA4	cytotoxic T-lymphocyte associated protein 4	CTLA4 inhibitory signaling RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)	Ipilimumab Tremelimumab	Type I diabetes mellitus Graves' disease Allograft rejection Hashimoto's thyroiditis
DAPP1	dual adaptor of phosphotyrosine and 3-phosphoinositides 1	Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Inositol 1,3,4,5-Tetrakisphosphate
DLG4	discs large MAGUK scaffold protein 4	Signaling by ERBB4 Trafficking of AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor NrCAM interactions Activation of Ca-permeable Kainate Receptor RHO GTPases activate CIT RAF/MAP kinase cascade LGI-ADAM interactions Neurexins and neuroligins Neurexins and neuroligins Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Guanidine Guanosine-5'-Monophosphate
DOK1	docking protein 1	PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 RET signaling
DOK2	docking protein 2	Tie2 Signaling RET signaling
DOK3	docking protein 3	Neutrophil degranulation
EGFR	epidermal growth factor receptor	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants	Cetuximab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib AV-412 S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE PD-168393 Afatinib Osimertinib Necitumumab Foreskin keratinocyte (neonatal) Depatuxizumab mafodotin Icotinib Neratinib Dacomitinib Fostamatinib Zalutumumab Brigatinib Olmutinib Zanubrutinib Abivertinib	Choriocarcinoma Gastric cancer Bladder cancer Oral cancer Glioma Laryngeal cancer Cervical cancer Esophageal cancer
EPOR	erythropoietin receptor	Signaling by Erythropoietin Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS	Darbepoetin alfa Erythropoietin Dibromotyrosine Peginesatide Methoxy polyethylene glycol-epoetin beta	Congenital polycythemia; Familial erythrocytosis (ECYT)
ERBB2	erb-b2 receptor tyrosine kinase 2	Signaling by ERBB2 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants	Trastuzumab Lapatinib IGN311 Trastuzumab emtansine Varlitinib AV-412 Pertuzumab Afatinib Tucatinib Tesevatinib Fostamatinib Brigatinib Margetuximab Zanubrutinib	Choriocarcinoma Pancreatic cancer Gastric cancer Bladder cancer Endometrial Cancer Ovarian cancer Cholangiocarcinoma Breast cancer Cervical cancer
ERBB3	erb-b2 receptor tyrosine kinase 3		Tucatinib	Lethal congenital contractural syndrome (LCCS) Type I diabetes mellitus
ERBB4	erb-b2 receptor tyrosine kinase 4		Afatinib Fostamatinib Brigatinib Zanubrutinib
EVL	Enah/Vasp-like	Generation of second messenger molecules Signaling by ROBO receptors Signaling by ROBO receptors RHO GTPases Activate Formins
FASLG	Fas ligand	Caspase activation via Death Receptors in the presence of ligand Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited Interleukin-4 and Interleukin-13 signaling Dimerization of procaspase-8 FasL/ CD95L signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models FOXO-mediated transcription of cell death genes TNFs bind their physiological receptors		Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
FCAR	Fc fragment of IgA receptor	Neutrophil degranulation
FCER1G	Fc fragment of IgE receptor Ig	GPVI-mediated activation cascade Cell surface interactions at the vascular wall Fc epsilon receptor (FCERI) signaling Fc epsilon receptor (FCERI) signaling Role of LAT2/NTAL/LAB on calcium mobilization Role of LAT2/NTAL/LAB on calcium mobilization FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization FCERI mediated NF-kB activation Dectin-2 family Dectin-2 family Neutrophil degranulation Platelet Adhesion to exposed collagen	Benzylpenicilloyl polylysine
FCGR2A	Fc fragment of IgG receptor IIa	FCGR activation FCGR activation Regulation of actin dynamics for phagocytic cup formation Role of phospholipids in phagocytosis Neutrophil degranulation FCGR3A-mediated IL10 synthesis	Cetuximab Etanercept Human immunoglobulin G Abciximab Alemtuzumab Daclizumab Bevacizumab Catumaxomab Sarilumab	Systemic lupus erythematosus
FCGR2B	Fc fragment of IgG receptor IIb	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	Etanercept Human immunoglobulin G Abciximab Tositumomab Alemtuzumab Antithymocyte immunoglobulin (rabbit) Palivizumab Daclizumab Bevacizumab Sarilumab	Systemic lupus erythematosus
FOLR1	folate receptor alpha	COPII-mediated vesicle transport Cargo concentration in the ER COPI-mediated anterograde transport	Folic acid Vintafolide Farletuzumab

Search Results for: LYN